Ignite Creation Date:
2025-12-24 @ 5:39 PM
Ignite Modification Date:
2026-01-03 @ 7:16 PM
Study NCT ID:
NCT03276468
Status:
COMPLETED
Last Update Posted:
2023-01-10
First Post:
2017-09-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
Sponsor:
The Lymphoma Academic Research Organisation
Organization:
Study Overview
Official Title:
A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multicenter phase II trial which primary objective is to assess the anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199, venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts:
* relapsed/refractory follicular lymphoma (FL) patients
* relapsed/refractory aggressive (DLBCL) lymphoma patients
* relapsed/refractory other indolent (iNHL) lymphoma patients (MZL and MALT)
* relapsed/refractory follicular lymphoma (FL) patients
* relapsed/refractory aggressive (DLBCL) lymphoma patients
* relapsed/refractory other indolent (iNHL) lymphoma patients (MZL and MALT)
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: